Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Treasury Shares (2017 - 2025)

Historic Treasury Shares for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $5.2 million.

  • Sutro Biopharma's Treasury Shares fell 1303.71% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 1303.71%. This contributed to the annual value of $6.0 million for FY2024, which is 1354.15% up from last year.
  • Sutro Biopharma's Treasury Shares amounted to $5.2 million in Q3 2025, which was down 1303.71% from $6.2 million recorded in Q2 2025.
  • Sutro Biopharma's 5-year Treasury Shares high stood at $6.2 million for Q2 2025, and its period low was $1.9 million during Q1 2021.
  • Its 5-year average for Treasury Shares is $4.4 million, with a median of $5.2 million in 2023.
  • Its Treasury Shares has fluctuated over the past 5 years, first skyrocketed by 26073.17% in 2021, then crashed by 3704.81% in 2025.
  • Quarter analysis of 5 years shows Sutro Biopharma's Treasury Shares stood at $2.4 million in 2021, then skyrocketed by 64.67% to $4.0 million in 2022, then skyrocketed by 32.5% to $5.2 million in 2023, then increased by 13.54% to $6.0 million in 2024, then dropped by 12.05% to $5.2 million in 2025.
  • Its Treasury Shares stands at $5.2 million for Q3 2025, versus $6.2 million for Q2 2025 and $3.9 million for Q1 2025.